new
treatment
multipl
sclerosi
ms
focus
b
cell
creat
atmospher
excit
ms
commun
b
cell
known
play
major
role
diseas
demonstr
highli
impact
effect
b
celldeplet
antibodi
control
ms
idea
viru
may
play
role
develop
ms
long
histori
support
mostli
studi
demonstr
link
b
celltrop
epsteinbarr
viru
ebv
diseas
onset
effort
develop
antivir
strategi
treat
ms
underway
although
gap
remain
understand
etiolog
ms
role
virus
propag
pathogen
immun
respons
deserv
attent
clinic
studi
show
deplet
b
cell
reduc
diseas
burden
relapsingremit
progress
multipl
sclerosi
ms
patient
ms
chronic
immunemedi
diseas
complex
etiolog
involv
dysregul
immun
system
bout
peripher
mediat
inflamm
well
ongo
central
nervou
system
cn
compartment
inflamm
lead
loss
neural
tissu
worsen
disabl
intermitt
wave
aberr
regul
andor
activ
immun
cell
subset
result
traffick
perivascular
infiltr
across
bloodbrain
barrier
bbb
cn
immun
cell
becom
reactiv
impact
underli
tissu
result
diseas
relaps
biolog
underpin
nonrelaps
progress
ms
well
understood
thought
least
part
driven
cnscompartment
inflamm
involv
persist
immun
cell
activ
around
perivascular
lesion
mening
respect
etiolog
ms
genet
suscept
environment
exposur
thought
involv
lifetim
incid
ms
gener
popul
rang
per
patientyear
concord
rate
ms
genet
ident
twin
rang
northern
popul
even
countri
itali
franc
highlight
contribut
genet
risk
also
import
environ
act
genet
predispos
host
cell
recent
b
cell
interact
shown
play
crucial
role
drive
new
relaps
highli
effect
diseas
control
observ
use
b
celldeplet
antibodi
ocrelizumab
reinforc
interest
develop
addit
b
cellmedi
treatment
build
success
studi
could
includ
design
execut
approach
target
implicit
role
b
celltrop
viru
ms
specif
environment
exposur
relev
trigger
ms
modul
diseas
cours
viru
infect
one
crucial
environment
factor
virus
consid
ms
pathogenesi
ebv
highli
b
celltrop
viru
beststudi
tabl
defect
control
ebv
associ
infecti
mononucleosi
im
addit
hodgkin
lymphoma
burkitt
lymphoma
gastric
cancer
nasopharyng
carcinoma
condit
associ
hiv
hairi
cell
leukemia
lymphoma
also
evid
infect
ebv
associ
transcript
factor
implic
ebv
nuclear
antigen
oper
across
differ
diseas
loci
link
higher
risk
autoimmun
diseas
ms
includ
system
lupu
erythematosu
rheumatoid
arthriti
gren
syndrom
ebv
appear
involv
across
clinic
spectrum
ms
includ
earli
pediatriconset
ms
establish
relapsingremit
rrm
progress
form
pm
well
patient
mild
sever
diseas
cours
box
viralinduc
anim
model
neuroinflamm
demyelin
neurodegener
provid
addit
proof
principl
virus
play
role
autoimmun
diseas
box
past
year
converg
studi
multipl
b
celltrop
virus
may
trigger
aberr
immun
respons
ms
genet
suscept
individu
owe
part
failur
viral
surveil
clearanc
compel
data
support
etiolog
role
viral
involv
ms
emerg
epsteinbarr
viru
ebv
target
mechan
ebv
thought
particip
ms
pathogenesi
provid
opportun
new
drug
develop
ms
investig
point
link
ebv
infect
develop
ie
etiolog
ms
ms
develop
absenc
exposur
ebv
ebv
requir
insuffici
contributor
earli
diseas
pathophysiolog
independ
support
come
observ
higher
rate
ebv
activ
ms
role
ebv
trigger
new
relaps
consist
reduc
abil
ebvspecif
cell
eg
cell
exhaust
see
glossari
limit
ebv
reactiv
ms
patient
strong
correl
presenc
antiebv
antibodi
blood
diseas
onset
evid
cn
involv
come
report
elev
igg
serolog
associ
appear
new
gadolinium
gd
enhanc
brain
lesion
presenc
patient
cell
recogn
myelin
addit
ebvinfect
b
cell
peripheri
contribut
relaps
diseas
ebv
may
play
crucial
role
propag
cnscompartment
inflamm
injuri
potenti
contribut
progress
nonrelaps
aspect
ms
b
cell
may
traffic
cn
also
cn
deep
cervic
lymph
node
b
cell
includ
infect
ebv
could
activ
aberr
cell
respons
peripheri
one
specul
ebv
cn
pool
may
contribut
cnscompartment
inflamm
also
diseas
relaps
support
content
evid
antibodi
cerebrospin
fluid
csf
ms
patient
recogn
ebv
antigen
evid
ebvinfect
b
cell
plasma
cell
accumul
ms
brain
mening
immunecel
collect
box
although
presenc
ebvinfect
b
cell
ms
brain
observ
studi
potenti
cell
particip
germin
center
gc
like
reaction
mening
could
support
ongo
immun
cell
activ
mainten
pool
pathogen
ebvinfect
cell
cn
preval
ebv
worldwid
reflect
overal
toler
effici
immun
control
viru
human
popul
ebv
commonli
establish
lifelong
latent
infect
human
b
cell
littl
advers
effect
ebv
also
known
human
herpesviru
member
famili
compris
eight
known
human
herpesvirus
one
common
dna
virus
found
human
infect
world
adult
popul
variou
intrins
properti
ebv
enabl
evad
immun
system
establish
latent
infect
b
memori
cell
ebv
achiev
util
seri
distinct
latenc
transcript
program
exploit
normal
b
cell
differenti
pathway
drive
infect
b
cell
transit
activ
b
cell
blast
latent
latenc
ii
infect
rest
memori
b
cell
sever
hypothes
propos
explain
ebv
infect
may
play
role
ms
pathophysiolog
tabl
ebv
may
involv
peripher
immun
respons
contribut
relaps
well
within
cn
part
cnscompartment
inflamm
like
crucial
progress
aspect
diseas
peripheri
ebv
may
contribut
aberr
evid
support
essenti
role
ebv
ms
deriv
studi
includ
pediatr
adultonset
patient
rrm
patient
spm
pm
well
aggress
form
ms
therefor
worth
review
associ
ebv
across
broad
spectrum
ms
cohort
clinic
isol
syndrom
ci
case
one
seroneg
studi
repres
largest
ebvci
popul
evalu
date
differ
studi
includ
ci
rrm
pm
evid
ebv
serolog
confirm
diagnosi
ms
support
come
recent
studi
et
al
report
associ
ebv
infect
earlyonset
ms
ebv
serolog
correl
earli
diagnost
convers
ci
ms
howev
neither
viral
capsid
antigen
vca
igg
antibodi
serum
ebv
dna
load
saliva
associ
radiolog
clinic
diseas
activ
ebv
infect
strongli
associ
pediatr
ms
herp
simpl
viru
hsv
seroposit
associ
pediatr
ms
case
neg
highlight
complex
natur
viral
exposur
genet
factor
multivari
analysi
studi
reveal
reduct
risk
develop
ms
associ
cmv
infect
influenc
ms
statu
associ
infect
taken
togeth
role
ebv
earli
ms
support
converg
pediatr
ms
studi
adult
ms
studi
consist
role
ebv
requir
insuffici
like
play
one
key
contribut
role
across
ms
spectrum
intersect
genet
suscept
addit
environment
factor
activ
traffick
cnsreactiv
immun
cell
result
diseas
relaps
molecular
mimicri
theori
describ
cell
prime
exposur
ebv
antigen
crossreact
recogn
attack
cn
antigen
anoth
theori
suggest
abcrystallin
may
recogn
mistakenli
selfprotein
hypothesi
describ
ebv
infect
peripher
b
cell
may
induc
express
abcrystallin
lymphoid
cell
trigger
cell
respons
abcrystallin
also
express
oligodendrocyt
anoth
theori
describ
potenti
ebv
preferenti
drive
proinflammatori
b
cell
cytokin
respons
eg
tumor
necrosi
factor
tnf
lymphotoxin
lt
granulocytemacrophag
colonystimul
factor
gmcsf
express
interfer
downregulatori
function
anoth
theori
base
abil
ebv
induc
express
ebvinduc
g
proteincoupl
receptor
support
part
migrat
autoreact
cell
ebvinfect
b
cell
cn
within
cn
ebv
may
contribut
propag
target
organ
inflamm
injuri
support
idea
ebv
could
elicit
bystand
damag
induc
antivir
immun
respons
infect
cell
cn
anoth
hypothesi
focus
ebv
may
play
cooper
pathogen
role
accord
theori
ebv
infect
astrocyt
may
activ
human
endogen
retrovirusw
hervw
msassoci
retroviru
msrv
addit
hypothesi
autoreact
b
cell
provid
unifi
principl
describ
ebv
infect
essenti
develop
ms
emerg
part
reduc
control
ebv
reinfect
exhaust
ebvspecif
cytotox
cell
defici
kill
ebv
cell
exhaust
result
accumul
ebvinfect
autoreact
b
cell
ms
brain
drive
inflamm
interact
autoreact
cell
anim
model
use
explor
virusspecif
mechan
contribut
autoimmun
demyelin
diseas
includ
ms
ebv
infect
mice
contribut
challeng
studi
role
ebv
model
cn
inflamm
includ
experiment
autoimmun
encephalomyel
eae
nevertheless
ebvlik
viru
murin
exacerb
eae
lead
type
ifndepend
increas
heparan
sulfat
respons
proliferationinduc
ligand
inhibit
viral
reactiv
theiler
murin
encephalomyel
viru
tmev
model
correl
infect
latestag
demyelin
entri
tmev
cn
contrast
ms
b
cell
deplet
tmev
model
caus
worsen
diseas
hint
prolong
b
cell
deplet
might
worsen
viral
infect
progress
disabl
ebv
also
upregul
antigenpres
machineri
infect
b
cell
facilit
crosspresent
immunogen
mog
peptid
cell
varieti
anim
model
ebvlik
virus
ebv
lead
develop
autoimmun
neurodegen
mslike
diseas
patholog
gland
patient
gren
syndrom
provid
gener
support
hypothesi
across
autoimmun
diseas
ebv
impact
msrelev
immun
respons
memori
b
cell
memori
cell
whose
interact
consid
play
key
role
diseas
pathophysiolog
theori
cnsautoreact
cell
may
activ
lymphoid
tissu
potenti
interact
ebvinfect
b
cell
migrat
cn
receiv
costimulatori
surviv
signal
ebvinfect
b
cell
enhanc
b
cellmedi
antigen
present
autoreact
cell
inhibit
apoptosi
may
contribut
persist
local
inflamm
includ
recruit
inflammatori
cell
togeth
result
antigendirect
injuri
well
bystand
injuri
cn
tissu
recent
studi
suggest
ms
memori
b
cell
drive
autoprolifer
type
helper
cell
brainhom
cell
recogn
autoantigen
b
cell
ms
lesion
cell
reportedli
migrat
brain
induc
inflamm
interact
hladr
ra
guanylreleas
protein
jelcic
colleagu
report
natalizumab
known
effect
treatment
ms
block
migrat
interestingli
impair
cell
expans
lead
suscept
ebv
infect
provid
potenti
link
antiebv
immun
expans
activ
cell
common
underli
theme
emerg
theori
ebvinfect
memori
b
cell
contribut
recognit
selfantigen
ms
brain
lead
propag
aberr
immun
respons
peripheri
cn
result
evolutionari
symbiot
relationship
virus
host
cell
develop
capac
coexist
coevolut
led
develop
mechan
allow
virus
escap
immun
surveil
result
prolong
viru
surviv
potenti
reactiv
infect
sever
studi
report
detect
ebvinfect
b
cell
plasma
cell
brain
ms
patient
earlier
studi
mening
b
cell
within
specif
structur
refer
tertiari
lymphoid
follicl
gclike
architectur
describ
major
site
ebv
persist
ms
brain
recent
presenc
ebv
ms
healthi
brain
report
veroni
identifi
widespread
ebv
infect
mening
ms
patient
ebvrel
gene
express
profil
associ
latent
ebv
infect
mening
white
matter
tissu
interest
report
detect
gene
express
ebvinfect
cell
associ
ifng
signal
type
immun
effector
function
b
cell
differenti
prolifer
lipidantigen
present
cell
myeloid
cell
recruit
anoth
studi
brain
ebv
detect
pcr
ebv
encod
region
eber
situ
hybrid
ish
ms
case
compar
nonm
sampl
detect
immunohistochemistri
ihc
ms
brain
section
lesser
extent
intermediateearli
ebv
transactiv
gene
note
studi
also
report
detect
ebv
astrocyt
microglia
virus
ebv
eg
cmv
detect
pcr
studi
analyz
express
ebv
latent
protein
well
protein
associ
lytic
infect
archiv
brain
sampl
ebvencod
protein
mrna
detect
ihc
situ
hybrid
ms
control
brain
ebv
earli
lytic
protein
observ
ms
nonm
sampl
latent
viru
describ
preval
ms
brain
lytic
viru
found
chronic
ms
plaqu
consist
role
ebv
diseas
pathogenesi
recent
studi
ebv
identifi
across
stage
ms
distribut
throughout
brain
variou
cell
type
shown
present
white
matter
within
mening
structur
despit
studi
presenc
ebv
ms
brain
remain
activ
area
debat
note
lassmann
et
al
contrast
result
variou
group
may
due
part
differ
method
employ
across
studi
includ
tissu
prepar
antibodi
use
detect
abil
preserv
detect
mening
structur
contain
ectop
b
cell
follicl
continu
next
page
gc
form
ebvinfect
cell
enter
resid
undetect
gc
memori
b
cell
ebvinduc
protein
latent
member
protein
play
key
role
process
interest
persist
ebvinfect
memori
b
cell
rel
minor
effect
gc
process
result
low
level
selfreact
polyreact
provid
ebv
distinct
advantag
allow
increas
number
memori
b
cell
thu
provid
everpres
popul
infect
cell
autoreac
cell
anoth
import
protein
consid
viral
homolog
present
serum
plasma
im
patient
normal
express
myeloid
cell
also
cell
b
cell
limit
autoimmun
inhibit
cell
growth
cell
express
interferon
ifn
g
cytokin
product
lipopolysaccharid
lp
stimul
monocyt
also
known
inhibit
apoptot
cell
death
im
nativ
signific
differ
activ
support
persist
immun
evas
ebv
human
cell
impair
natur
killer
nk
cellmedi
kill
infect
b
cell
interfer
cell
activ
modul
cytokin
respons
also
reduc
antigen
present
recognit
newli
infect
cell
ebvspecif
cell
appear
diminish
immunogen
ebv
initi
prelat
phase
infect
therebi
strengthen
establish
latent
ebv
infect
immun
evas
provid
ebv
unusu
long
lifespan
human
cell
major
surviv
benefit
ebv
catastroph
human
lead
develop
cancer
autoimmun
diseas
seriou
ill
effect
control
ebv
infect
propos
mean
prevent
cure
autoimmun
diseas
ms
control
ebv
infect
could
accomplish
b
cell
deplet
antivir
drug
boost
immun
improv
immun
surveil
sever
antivir
compound
evalu
treatment
ms
includ
limit
famciclovir
stavudin
zidovudin
abacavir
raltegravir
use
antivir
compound
encourag
part
effect
treat
aidshiv
associ
herv
ms
antiebv
effect
includ
inhibit
ebv
dna
replic
famciclovir
acyclovir
effect
treat
herp
zoster
shingl
chickenpox
genit
herp
evalu
treatment
ms
fail
placebocontrol
studi
rrm
antiherpesvir
nucleosid
analog
acyclovir
penciclovir
ganciclovir
also
receiv
attent
unfortun
studi
ms
discourag
fail
show
effect
diseas
activ
reason
lack
efficaci
may
due
low
impact
given
viru
diseas
challeng
studi
design
includ
mechan
action
moa
specif
agent
inactiv
viral
kinas
limit
durat
studi
singl
agent
versu
combin
antivir
drug
eg
effect
hiv
small
sampl
size
continu
report
highlight
evid
hhv
herv
involv
ms
case
report
remiss
warrant
studi
particularli
larger
studi
necessari
exist
studi
design
show
clinic
efficaci
reader
remind
potent
antivir
protein
human
ifnb
remain
one
top
five
treatment
option
ms
moa
ifnb
ms
clear
thought
involv
antiinflammatori
mechan
nevertheless
ifnb
known
inhibit
infect
ebv
cytomegaloviru
cmv
virus
influenc
prolif
cell
respons
decreas
memori
b
cell
compart
consid
pathogen
cell
subset
key
trigger
ms
tempt
suggest
moa
ifnb
diseasemodifi
therapi
dmt
includ
overlap
antivir
antiinflammatori
mechan
support
futur
simultan
test
ms
drug
diverg
moa
histori
full
exampl
erad
human
diseas
vaccin
mean
control
viral
propag
present
avail
vaccin
protect
ebv
infect
one
possibl
approach
develop
vaccin
would
target
viral
protein
small
trial
evalu
vaccin
ebv
show
limit
result
ms
recent
advanc
vaccin
focu
genom
vaccin
abl
deliv
multipl
proteincod
sequenc
could
help
advanc
vaccin
studi
ms
lesson
learn
monitor
clinic
studi
underway
use
genom
vaccin
test
safeti
immunogen
ebola
viru
hepat
c
viru
breast
brain
cancer
prospect
develop
prophylact
vaccin
block
prevent
acut
ebv
infect
strategi
prevent
develop
ms
nevertheless
appeal
although
also
fraught
major
challeng
challeng
design
ebv
vaccin
provid
steril
immun
herpesviru
almost
improb
endpoint
ideal
vaccin
prevent
acut
im
may
suffici
reduc
risk
develop
ms
recent
studi
herpesviru
vaccin
provid
promis
result
support
concept
design
vaccin
prevent
diseas
rather
infect
may
possibl
challeng
exist
develop
ebv
vaccin
effort
begun
may
yield
surpris
result
antibodi
recogn
ebv
protein
express
latenc
includ
would
increas
immun
ebv
date
studi
focus
control
ebv
infect
use
antibodi
direct
ebvspecif
protein
report
viral
target
could
obtain
seri
genomewid
associ
studi
gwa
identifi
variant
contribut
ms
diseas
suscept
addit
grow
wealth
human
genet
data
group
viral
interactom
transcriptom
b
cell
ebvinfect
b
cell
may
use
select
new
target
especi
ebv
genet
variant
associ
ms
target
b
cell
pathway
eg
baff
employ
sirna
target
ebv
gene
eg
downregul
express
induc
apoptosi
ebvinfect
cell
might
also
effect
reduc
ebv
reactiv
cellbas
immunotherapi
especi
target
ebvinfect
transform
cell
shown
efficaci
similar
benefit
may
result
treat
autoimmun
diseas
ms
cellbas
immunotherapi
aim
reduc
ebv
reactiv
especi
immunotherapi
target
cell
type
known
implic
diseas
patholog
encourag
note
studi
underway
cellbas
therapi
includ
deplet
immun
system
via
immunoabl
follow
mesenchym
relat
stem
cell
transplant
autolog
hematopoiet
stem
cell
transplant
transplant
oligodendrocyt
progenitor
cell
introduct
endogen
stem
cell
follow
enhanc
repar
capabl
although
potenti
breakthrough
treatment
approach
methodolog
ethic
challeng
design
studi
understand
potenti
benefit
safeti
concern
limit
therebi
releg
approach
aggress
hardtotreat
ms
treatment
desper
need
avail
recent
applic
autolog
allogen
cell
therapi
target
ebvinfect
b
cell
use
ebvspecif
cytotox
cell
therapi
provid
altern
cellbas
approach
exampl
demonstr
patient
secondari
progress
ms
spm
infus
ebvspecif
cytotox
cell
advers
effect
individu
show
clinic
improv
reduc
diseas
activ
magnet
reson
imag
mri
decreas
intrathec
immunoglobulin
product
highlight
likelihood
treatment
effect
occur
cn
accompani
increas
percent
circul
lmp
blymphoblast
cell
line
lcl
reactiv
effector
memori
cell
popul
success
observ
studi
led
phase
clinic
trial
autolog
ebvspecif
cell
therapi
progress
ms
author
note
seriou
advers
effect
includ
diseas
exacerb
also
report
seven
treat
patient
show
clinic
improv
phase
studi
evalu
safeti
allogen
ebvspecif
cytotox
cell
therapi
subject
rrm
progress
ms
underway
advantag
cellbas
approach
target
ebvinfect
cell
includ
limit
offtarget
effect
potenti
target
infect
b
cell
peripheri
cn
perhap
provid
benefit
relaps
nonrelaps
progress
ms
anoth
regist
studi
underway
assess
safeti
feasibl
adopt
cell
therapi
autolog
ebvspecif
cytotox
lymphocyt
ctl
patient
first
clinic
episod
highli
suggest
ms
ii
purpos
studi
develop
immun
intervent
capabl
restor
hostebv
balanc
studi
assess
feasibl
safeti
autolog
transfer
sever
concentr
cell
direct
autolog
ebvtransform
b
cell
line
restor
effici
control
ebv
reactiv
ms
patient
cellbas
therapi
repres
innov
excit
tactic
control
ms
outcom
ongo
studi
much
anticip
may
open
door
vastli
differ
treatment
approach
kept
mind
cellbas
treatment
ms
need
excel
safeti
profil
durat
effect
distinct
advantag
current
avail
treatment
mani
approv
diseasemodul
therapi
ms
understood
direct
andor
indirect
impact
memori
b
cell
memori
cell
whose
interact
thought
play
key
role
diseas
pathophysiolog
recent
import
b
cell
involv
ms
strongli
support
clinic
studi
iii
iv
v
vi
use
b
celldeplet
antibodi
ocrelizumab
substanti
reduc
annual
relaps
rate
dramat
limit
appear
new
gdenhanc
new
lesion
well
delay
progress
disabl
ocrelizumab
repres
breakthrough
treatment
ms
impact
limit
diseas
activ
cn
injuri
select
target
b
cell
would
consist
pathophysiolog
role
ebvinfect
b
cell
ms
unclear
whether
ocrelizumab
modul
regul
activ
traffick
memori
b
cell
broadli
deplet
interest
specul
extent
observ
benefit
reflect
impact
therapi
ebvmedi
diseas
mechan
cellbas
therapi
select
target
subset
b
cell
infect
ebv
could
provid
innov
approach
achiev
potenti
implic
treat
relaps
progress
form
ms
perhap
even
prevent
develop
ms
none
environment
factor
genet
suscept
variant
identifi
suffici
isol
caus
diseas
instead
diseas
onset
appear
involv
combin
factor
constitut
perfect
storm
result
dysregul
autoimmun
inflamm
cn
harm
inflamm
occur
peripheri
cn
central
ms
pathophysiolog
contribut
relaps
diseas
nonrelaps
progress
diseas
respect
understand
b
cell
involv
ms
effort
focus
natur
aberr
intrathec
antibodi
respons
analysi
oligoclon
band
net
synthesi
immunoglobulin
within
cn
larg
driven
increas
use
experiment
autoimmun
encephalomyel
eae
anim
model
ms
cellcentr
view
ms
pathophysiolog
current
ms
diseas
patholog
thought
invok
key
interact
b
cell
particularli
memori
subset
support
converg
clinic
trial
result
laboratorybas
studi
high
tropism
ebv
b
cell
mechan
immun
avoid
serv
promot
longterm
surviv
persist
viru
memori
b
cell
fundament
alter
b
cell
biolog
result
persist
accumul
diseaserelev
ebvinfect
autoreact
b
cell
ebv
may
contribut
episod
peripher
mediat
inflamm
underli
diseas
relaps
associ
perivascular
cn
injuri
well
persist
cnscompartment
inflamm
mening
thu
contribut
diffus
nonrelaps
progress
injuri
ultim
proof
come
intervent
studi
select
elimin
andor
modul
ebvinfect
memori
b
cell
far
clear
whether
antivir
therapi
target
ebv
virus
provid
benefit
ms
clinician
corner
nevertheless
involv
virus
autoimmun
diseas
remain
understudi
despit
long
histori
report
implic
virus
process
lead
inflamm
continu
research
warrant
role
ebv
ms
also
virus
gener
impact
autoimmun
diseas
see
outstand
question
sever
effect
treatment
ms
avail
recent
introduc
therapi
aim
deplet
b
cell
ocrelizumab
provid
excel
control
diseas
repres
import
advanc
treatment
ms
b
cell
deplet
effici
suppress
acut
inflammatori
diseas
activ
rrm
unlik
mani
establish
treatment
may
also
slow
progress
disabl
progress
ms
addit
approach
evalu
focu
deplet
pathogen
subset
b
cell
either
blockad
b
cell
prolifer
viral
reactiv
pathway
eg
b
cellactiv
factor
antagonist
sirna
target
b
celltrop
virus
use
cellbas
method
slow
ultim
halt
progress
injuri
associ
ms
remain
major
challeng
concern
patient
treat
neurologist
avail
treatment
improv
qualiti
life
measur
part
reduc
frequenc
clinic
exacerb
limit
develop
focal
inflammatori
lesion
rel
littl
effect
delay
disabl
clinic
studi
design
best
captur
reliabl
measur
progress
disabl
studi
potenti
benefit
b
celldirect
therapi
aim
control
ebv
immun
research
focus
understand
role
mening
immunecel
aggreg
ms
brain
includ
possibl
role
ebvinfect
b
cell
form
aggreg
relationship
diseas
patholog
mechanist
contribut
ebv
develop
ms
impact
establish
diseas
instanc
ebv
seroposit
ms
well
establish
therefor
previou
infect
ebv
necessari
insuffici
develop
ms
regard
best
way
design
clinic
studi
prove
target
ebv
viral
exposur
gener
would
effect
ms
treatment
cure
